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Although the causal nature of the relation
between lead exposure and elevated blood
pressure in adults is still debated [Agency
for Toxic Substances and Disease Registry
(ATSDR) 1999; Den Hond et al. 2002,
2003; Vupputuri et al. 2003], a meta-analysis
of about 60,000 subjects from 31 studies
estimated that a doubling of blood lead con-
centration was associated with a 1.0 mmHg
[95% confidence interval (CI), 0.5 to 1.4
mmHg] rise in systolic pressure and a 0.6
mmHg (95% CI, 0.4 to 0.8 mmHg) rise in
diastolic pressure (Nawrot et al. 2002).
Children generally have higher blood lead
concentrations, but data on the relation
between blood lead concentration and blood
pressure in them are sparse and were not
included in the meta-analysis because “blood
pressure in children is highly variable and cor-
relates highly with height” (Nawrot et al.
2002).
One 1970s study showed that children
with blood lead concentrations > 40 µg/dL
had higher systolic (but not diastolic) blood
pressure (Jhaveri et al. 1979), but other stud-
ies did not detect any positive association
between blood lead and blood pressure in
children < 10 years of age (Friedlander et al.
1981; Rogan et al. 1978; Selbst et al. 1993).
These early studies all had < 150 subjects and
did not adequately control confounding. A
contemporary study of 282 children 5.5 years
of age in Kosovo, in the former Yugoslavia,
did adjust for several covariates with multiple
regression (Factor-Litvak et al. 1996). That
study showed that a 10-µg/dL increase in
blood lead concentration was associated with
a 0.5-mmHg (95% CI, –0.2 to 1.3 mmHg)
increase in systolic and a 0.4-mmHg (95%
CI, –0.1 to 0.9 mmHg) increase in diastolic
blood pressure (Factor-Litvak et al. 1996).
The authors claim that these results suggest
but do not demonstrate a weak association
(Factor-Litvak et al. 1996).
Blood lead concentration peaks at about
2 years of age and then declines, whereas
blood pressure increases with age. It is plausi-
ble that the relation between blood lead and
blood pressure differs in childhood and adult-
hood, or that it is unstable in childhood, and
thus difficult to characterize with one meas-
urement. Repeated measurements of blood
lead and blood pressure in the same child
might then be informative. In addition, if lead
does increase blood pressure and the effect is
acute or subacute and reversible, then the rela-
tion will be more apparent when body lead
burden changes, such as during chelation.
We used data from a large, randomized
study of chelation therapy for lead exposure to
answer three questions: Does a sudden and
substantial decrease in blood lead induced by
chelation have any effect on blood pressure? Is
a sustained but modest lowering of blood lead
over a 6–9 month period associated with a
change in blood pressure? And is there any
association between concurrent blood lead and
blood pressure over 5 years of follow-up in
young children with signiﬁcant, but variable,
lead exposures?
Materials and Methods
The Treatment of Lead-Exposed Children
(TLC) trial is a randomized, placebo-controlled,
double-blind clinical trial of 780 children
12–33 months of age (mean age, 2 years) with
moderately high blood lead concentrations
(20–44 µg/dL) to test the effect of chelation
on cognitive function and behavior (TLC
1998). Four clinical centers, in Baltimore,
Maryland; Cincinnati, Ohio; Newark, New
Jersey; and Philadelphia, Pennsylvania, partici-
pated in the enrollment, treatment, and fol-
low-up. Three hundred ninety-six children
were treated with succimer (Chemet; McNeil
Laboratories, Fort Washington, PA), an oral
lead chelator, for up to three 26-day rounds
(75% of children received a second round of
drug, and 81% of those receiving a second
round of treatment received a third); 384 were
given placebo for similar periods. The study
was approved by the institutional review
boards at the clinical centers, Harvard School
of Public Health, Centers for Disease Control
and Prevention, and National Institute of
Environmental Health Sciences. The parents
of all the children provided written informed
consent at enrollment. Succimer decreased
blood lead level for several months but had
no effect on IQ or neurobehavioral test scores
at 36 months (about 5 years of age) and
60 months (about 7 years of age) after initia-
tion of treatment (Dietrich et al. 2004; Rogan
et al. 2001).
Blood lead concentration measurements.
Blood lead concentrations were measured at
baseline and days 7, 28, and 42 after the begin-
ning of each round of treatment. Blood lead
concentrations were also measured at 3- to
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Studies in children suggest a weak association between blood lead concentration and blood pressure.
To understand this better, we tested the strength of the association in children with elevated blood
lead concentrations and whether succimer chelation changed blood pressure as it did blood lead. In a
randomized clinical trial of 780 children with blood lead concentrations of 20–44 µg/dL at
12–33 months of age, we compared the systolic and diastolic blood pressure in the succimer-treated
group and placebo group for up to 5 years of follow-up. We also analyzed the relation of blood lead
to blood pressure. Children in the succimer group had lower blood lead concentrations for
9–10 months during and after treatment, but their blood pressure did not differ from those in the
placebo group during this period. During 1–5 years of follow-up, children in the succimer group had
systolic blood pressure 1.09 (95% conﬁdence interval, 0.27–1.90) mmHg higher than did untreated
children in a model with repeated measurements, but the difference in diastolic blood pressure was
not statistically significant. No association between blood lead and blood pressure was found.
Overall, there is no association between blood lead and blood pressure in these children with
moderately high lead exposure, nor does chelation with succimer change blood pressure. Key words:
blood pressure, chelation, child, lead, succimer. Environ Health Perspect 114:579–583 (2006).
doi:10.1289/ehp.8634 available via http://dx.doi.org/ [Online 24 January 2006]4-month intervals for 5 years of follow-up.
The Nutritional Biochemistry Branch at the
Centers for Disease Control and Prevention in
Atlanta did the blood lead analyses by atomic
absorption spectrometry based on the methods
described by Miller et al. (1987).
Blood pressure measurements. At each visit
for blood lead measurement, study nurses also
measured systolic and diastolic blood pres-
sures. A Dinamap Vital Signs Monitor (an
automatic device; Critikon, Inc., Tampa, FL)
was used for all blood pressure measurements.
Blood pressure was measured when children
were seated. The average of up to three meas-
urements per visit (without a notation that the
child was crying or not staying still) was used
for statistical analysis. The overall average
number of blood pressure measurements per
visit was 2.2. At 36- and 60-month follow-
ups, three blood pressure measurements were
acquired from all subjects. Study nurses were
blinded to treatment status of children.
Statistical analysis. We first tested the
hypothesis that succimer lowered blood pres-
sure by comparing the succimer and placebo
groups immediately after initiation of treat-
ment and at the subsequent follow-ups. We
used multiple regression models of blood
pressure by treatment groups to obtain the
adjusted difference in blood pressures between
treatment and placebo groups at each visit
(baseline, during treatment, and at follow-up).
Covariates adjusted for included clinical center,
baseline blood lead concentration, race (black,
nonblack), sex, parents’ education (< 12 years,
12 years, ≥ 13 years), single parent (yes, no),
age at blood pressure measurement (in years),
height, and body mass index (BMI) at meas-
urements (Factor-Litvak et al. 1996; Sinaiko
1996). Mixed models with similar covariate
adjustment were used to obtain adjusted
regression estimates accounting for repeated
measurements of blood pressure (using
repeated statement in the modeling). The
effects of baseline blood lead concentration and
age at blood pressure measurement were mod-
eled as ﬁxed effects. Unstructured covariance
structure was used in the mixed models by
Akaike’s information criterion (Akaike 1974).
Because the difference in blood lead concentra-
tions between the succimer and placebo groups
lasted 9–10 months after initiation of treat-
ment, the interval from initiation of treatment
to 9-month follow-up (not including baseline)
and the interval from 12- to 60-month follow-
up were modeled separately.
The trial data set is also a large observa-
tional cohort data set, so we also wanted to
examine the relation between blood lead con-
centration and blood pressure in these data. To
do this, we tested whether concurrent blood
lead concentration was associated with blood
pressure at various time points adjusted for
treatment group and other covariates (clinic
centers, race, sex, parents’ education, single
parent, age at blood pressure measurement,
height, and BMI). Scatter plots of blood pres-
sure by blood lead concentration and plots of
residual versus predicted values of regression
models supported a linear relation between
blood lead concentration and blood pressure,
so linear regression models were used. We also
did mixed models with repeated blood lead
and blood pressure measurements to test their
association for two above-mentioned intervals
separately.
We used software R (version 2.0; R
Development Core Team 2004) for smooth
curve fitting and graphics; and SAS (version
9.0; SAS Institute Inc. Cary, NC) for general
statistics, multiple regression models, and
mixed models.
Results
Of 780 enrollees, 44% were female, 77% were
African American, 72% lived with a single
parent, and 40% had parents with < 12 years
of education. At baseline (mean ± SD), their
height was 85.7 ± 5.8 cm, BMI was 16.7
± 1.8 kg/m2, and age at blood lead and blood
pressure measurement was 2.0 ± 0.5 years. No
differences in these baseline characteristics
were seen between treatment groups.
At baseline, the mean blood lead concen-
tration of 780 children was 26 ± 5 µg/dL; there
was no difference between the succimer and
placebo groups in blood lead concentration at
baseline. After initiation of treatment, children
in the succimer group had lower blood leads
than did those in the placebo group for about
9–10 months. The two groups then had simi-
lar blood lead concentrations until the end of
study at 60-month follow-up.
Over the 5 years starting from randomiza-
tion, the children’s blood lead concentrations
declined by 70% (at 60-month follow-up, the
mean blood lead concentration was 8 ± 4
µg/dL, but blood pressure changed little. Of
704 children (both succimer and placebo
Chen et al.
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Table 1. Regression estimates [β (95% CI)] of blood pressure by treatment groups (succimer vs. placebo) in TLC trial children.
Systolic (mmHg) Diastolic (mmHg)
Visit No. Unadjusted Adjusteda Unadjusted Adjusteda
Baseline 704 –0.54 (–2.54 to 1.47) –0.80 (–2.27 to 1.17) 0.31 (–1.37 to 1.98) 0.15 (–1.50 to 1.80)
Treatment
Day 7 of 1st round 509 0.05 (–2.23 to 2.33) –0.37 (–2.58 to 1.84) –0.14 (–2.04 to 1.75) –0.86 (–2.70 to 0.99)
Day 28 of 1st round 429 0.05 (–2.37 to 2.47) 0.13 (–2.27 to 2.53) 0.77 (–1.33 to 2.87) 0.55 (–1.53 to 2.63)
Day 42 of 1st round 631 0.81 (–1.04 to 2.67) 0.54 (–1.24 to 2.32) 1.54 (–0.09 to 3.16) 1.16 (–0.43 to 2.76)
Follow-up
6 months 365 1.19 (–1.04 to 3.43) 1.10 (–1.02 to 3.21) 1.44 (–0.37 to 3.24) 1.32 (–0.48 to 3.11)
12 months 597 0.87 (–0.77 to 2.51) 0.87 (–0.66 to 2.40) 0.90 (–0.31 to 2.12) 0.87 (–0.36 to 2.09)
18 months 335 0.76 (–1.23 to 2.75) 0.89 (–0.95 to 2.73) –0.48 (–1.94 to 0.98) –0.44 (–1.88 to 1.01)
24 months 607 0.40 (–1.10 to 1.90) 0.64 (–0.66 to 1.94) –0.81 (–1.88 to 0.25) –0.79 (–1.81 to 0.23)
36 months 647 0.43 (–1.08 to 1.95) 1.27 (0.06 to 2.48)* 0.54 (–0.49 to 1.57) 0.74 (–0.26 to 1.74)
60 months 569 1.57 (–0.09 to 3.22) 1.69 (0.34 to 3.04)* 0.36 (–0.78 to 1.50) 0.30 (–0.80 to 1.39)
Estimates are estimated differences between succimer and placebo children.
aAdjusted for clinical center, baseline blood lead level, race, sex, parents’ education, single parent, age at test, height, and BMI. *p < 0.05.
Figure 1. Systolic (A) and diastolic (B) blood pressure by treatment group at baseline, days 7 and 42 of ﬁrst
round of treatment, and 6-, 36-, and 60-month follow-ups in TLC trial children. Error bars represent upper
bound of 95% CI of the mean blood pressure. Numbers within bars are blood lead concentrations (µg/dL)
of each group at these time points.
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measurement at baseline, the mean systolic
blood pressure was 100.7 ± 13.5 mmHg and
the mean diastolic blood pressure was 60.3
± 11.3 mmHg. No difference of blood pres-
sure between succimer and placebo groups at
baseline was observed. Figure 1 shows the
mean systolic and diastolic blood pressure by
treatment group at baseline, days 7 and 42 of
the first round of treatment, and at 6-, 36-,
and 60-month follow-ups. Although the
blood lead concentration declined sharply in
the succimer group at day 7 of the ﬁrst round
of treatment, blood pressure in the succimer
group did not differ from that in the placebo
group. Also, there was no difference in blood
pressure between the two treatment groups at
other time points. The results of regression
models estimating differences in blood pres-
sure between treatment groups (succimer vs.
placebo) at different time points are shown in
Table 1. For simplicity, results at only base-
line, first round of treatment, and 6-, 12-,
18-, 24-, 36-, and 60-month follow-ups
(when more children were measured) are pre-
sented. There were slight, statistically signiﬁ-
cant differences between succimer and
placebo groups in systolic blood pressure at
the 36- and 60-month follow-up visits, but
only after adjustment for covariates. In these
multiple regression models, baseline blood
lead level was generally not associated with
later blood pressure, whereas height and BMI
were usually positively associated with blood
pressure. Mixed models with adjustment of
covariates showed that, for the interval from
initiation of treatment to 9-month follow-up,
the overall difference between the succimer
and placebo groups is 0.24 mmHg (95% CI,
–0.79 to 1.28 mmHg) for systolic blood
pressure and 0.46 mmHg (95% CI, –0.44 to
1.36 mmHg) for diastolic blood pressure
(both p > 0.05). Adjusted mixed models for
the interval from 12-month to 60-month
follow-up indicated a higher systolic blood
pressure for the succimer group, with an esti-
mated difference of 1.09 mmHg (95% CI,
0.27–1.90 mmHg; p < 0.05); the estimated
difference in diastolic blood pressure is
0.15 mmHg (95% CI, –0.45 to 0.75 mmHg;
p > 0.05).
The cross-sectional association of blood
lead levels and blood pressure were ﬁrst plot-
ted with data from baseline and 36- and
60-month follow-ups (Figure 2). Spline
regression predictions are also shown. There
was no obvious association between blood lead
level and blood pressures at these age points.
The parametric regression estimates from
baseline, ﬁrst round of treatment, and 6-, 12-,
18-, 24-, 36-, and 60-month follow-ups are
shown in Table 2. At day 7 of the ﬁrst round
of treatment, blood lead concentration was
associated with systolic blood pressure in an
unadjusted analysis, but the association became
nonsigniﬁcant after adjustment for covariates.
Taking into account repeated measurements of
each individual and adjusting for covariates, a
mixed model using the interval between ini-
tiation of treatment and 9-month follow-up
showed regression estimates of –0.16 mmHg
(95% CI, –0.69 to 0.38 mmHg) in systolic
blood pressure and 0.19 mmHg (95% CI,
–0.27 to 0.66 mmHg) in diastolic blood
pressure per 10-µg/dL blood lead increase.
Using intervals from 12- to 60-month follow-
up, the estimates of per 10-µg/dL blood lead
increase were 0.01 mmHg (95% CI, –0.57 to
0.58 mmHg) in systolic blood pressure and
0.003 mmHg (95% CI, –0.45 to 0.45 mmHg)
in diastolic blood pressure. None of these
estimates in both intervals was statistically
signiﬁcant (all p > 0.05).
Discussion
Using data from a large clinical trial of chil-
dren with moderately high lead exposure, we
found that succimer treatment did not change
blood pressure from initiation of treatment
through 9 months after treatment, although it
decreased blood lead. In the interval from
1 year after treatment to 5 years after treat-
ment, however, children in the succimer
group had a 1-mmHg increase in systolic
blood pressure compared with children given
placebo; there was no difference in diastolic
Lead and blood pressure in children
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Figure 2. Scatter plots of systolic and diastolic blood pressure by concurrent blood lead concentration at baseline (A) and 36-month (B) and 60-month (C) follow-up.
Solid lines are spline regression estimates without covariate adjustment, and dashed lines are their 95% CIs.
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Table 2. Regression estimates [β (95% CI)] of blood pressure change per 10 µg/dL of elevation in concurrent blood lead level in TLC trial children.
Systolic (mmHg) Diastolic (mmHg)
Visit Unadjusted Adjusteda Unadjusted Adjusteda
Baseline 1.19 (–0.76 to 3.15) 1.36 (–0.58 to 3.30) 1.25 (–0.38 to 2.88) 1.47 (–0.16 to 3.10)
Treatment
Day 7 of 1st round 1.41 (0.13 to 2.69)* 1.26 (–0.27 to 2.78) 1.05 (–0.01 to 2.12) 1.14 (–0.13 to 2.41)
Day 28 of 1st round 0.02 (–1.50 to 1.53) 0.21 (–1.53 to 1.95) 0.22 (–1.10 to 1.54) 0.73 (–0.78 to 2.23)
Day 42 of 1st round –0.27 (–1.69 to 1.15) 0.07 (–1.33 to 1.47) 0.69 (–0.56 to 1.94) 1.19 (–0.07 to 2.44)
Follow-up
6 months 1.14 (–0.68 to 2.95) 0.62 (–1.13 to 2.37) 0.41 (–1.06 to 1.88) 0.33 (–1.15 to 1.81)
12 months 0.48 (–0.81 to 1.77) 0.24 (–0.97 to 1.46) –0.29 (–1.24 to 0.66) –0.28 (–1.26 to 0.69)
18 months 0.73 (–0.90 to 2.36) 0.81 (–0.70 to 2.31) –0.30 (–1.50 to 0.89) –0.34 (–1.52 to 0.85)
24 months –0.27 (–1.47 to 0.94) –0.68 (–1.76 to 0.39) 0.14 (–0.71 to 1.00) 0.32 (–0.52 to 1.16)
36 months 0.08 (–1.38 to 1.54) –0.72 (–1.91 to 0.48) –0.37 (–1.36 to 0.63) –0.44 (–1.43 to 0.56)
60 months –0.17 (–2.19 to 1.85) 0.01 (–1.71 to 1.73) –0.34 (–1.72 to 1.05) 0.15 (–1.25 to 1.55)
aAdjusted for clinical center, treatment group, race, sex, parents’ education, single parent, age at test, height, and BMI. *p < 0.05.blood pressure. Analysis of most visits and
mixed models considering repeated measure-
ments did not show any consistent association
between concurrent blood lead levels and
blood pressures in children 2–7 years of age.
Overall, the results suggest no association
between blood lead and blood pressure in
young children.
Lead exposure in experimental animals
induces hypertension (Chai and Webb 1988;
Ding et al. 1998; Preuss et al. 1994; Staessen
et al. 1994; Victery 1988; Victery et al.
1982b). The possible mechanisms are intra-
cellular perturbation of calcium metabolism
at end arterioles and effects on the renin–
angiotensin system (Sharp et al. 1987). The
lead and blood pressure association has been
seen in occupationally exposed workers (de
Kort et al. 1987; Telisman et al. 2004), the
general adult population (Cheng et al. 2001;
Vupputuri et al. 2003), pregnant women
(Rothenberg et al. 2002), and peri-menopausal
women (Nash et al. 2003), but the literature is
not entirely consistent (ATSDR 1999; Hertz-
Picciotto and Croft 1993). In children, our
study does not support an association between
blood lead and blood pressure. The TLC trial
children at enrollment had a mean blood lead
concentration of 26 µg/dL, and it could be that
the exposure level of lead is not high enough
to produce effect on blood pressure. In the
Kosovo study, children from the lead-exposed
town had mean blood lead levels of 37 µg/dL,
whereas children from the unexposed town
had that of 9 µg/dL, but the blood pressure did
not differ by town of residence. Also, when
data from two towns were combined, the rela-
tion between blood lead and blood pressure
was not statistically signiﬁcant (Factor-Litvak
et al. 1996). A much higher blood lead con-
centration (range, 40–90 µg/dL), as seen in
the Jhaveri et al. (1979) study of children
1–3 years of age, may be detrimental to blood
pressure, but our study could not test this
hypothesis. In animal studies, in utero and
postnatal exposure to 100 ppm lead in drink-
ing water increased blood pressure, but expo-
sure to 5 or 25 ppm did not, although renin
activity was increased to 25 ppm (Victery et al.
1982a, 1982b). The 100-ppm dose group
resulted in a blood lead concentration of
40 µg/dL, whereas the 25-ppm dose group had
an average of 18 µg/dL. The hypertension
effect seen in the high-dose group may be sec-
ondary to the renal lesion caused by continu-
ous high exposure rather than being a direct
effect (Victery 1988). Another possible reason
for the null association observed in our study is
that children with moderate lead exposure may
not show elevated blood pressure until a later
age, but we do not have data after 7–8 years of
age. A previous report of 50-year follow-up of
children with plumbism found a higher risk
for hypertension in adulthood compared with
controls, suggesting a very long induction
period (Hu 1991).
It is also possible that we failed to detect
an existing relation between blood lead and
blood pressure. Although we have the largest
sample size so far in published studies of blood
lead and blood pressure in children (Factor-
Litvak et al. 1996; Friedlander et al. 1981;
Jhaveri et al. 1979; Rogan et al. 1978; Selbst
et al. 1993), we only have power of 0.8 to
detect a 2-mmHg difference in blood pressure
between treatment and placebo groups for a
given cross-sectional comparison. Similarly,
for the regression model of blood pressure
by blood lead, cross-sectional analysis at each
time point was underpowered to detect a shal-
low slope. We did use repeated measurements
of blood lead and blood pressure analyzed
with a mixed model in an attempt to mitigate
this concern. Even so, in our study, we may
not have enough power to detect a slope of
0.5 mmHg per 10 µg/dL blood lead level as
seen in the Yugoslavia study (Factor-Litvak
et al. 1996). Use of an automated blood pres-
sure monitor in our study is another concern.
Although it is not the clinical standard, it can
be used as a screening tool or in epidemiologic
study of children (Gillman and Cook 1995;
National High Blood Pressure Education
Program 2004). The Yugoslavia study also
used an automated monitor for blood pressure
measurements (Factor-Litvak et al. 1996).
The TLC trial was designed to test the
hypothesis that children with moderate blood
lead levels receiving succimer treatment would
have better scores on tests of cognition and
behavior than children on placebo. Because no
difference in cognitive and behavioral scores
was observed between succimer and placebo
groups (Dietrich et al. 2004; Rogan et al.
2001), we examined blood pressure, an inter-
esting but not primary outcome in the trial.
The finding of no change in blood pressure
raises the questions whether the length and
dose of treatment were enough to induce
changes, whether new exposure to lead was
effectively prevented, or whether the lead
effects on blood pressure, if they exist, are
likely to be reversible. In this trial, we used
higher doses for a longer time than on the
Chemet (succimer) label, and it is unlikely
other chelation regimens are more effective
(Rogan et al. 2001). However, even with this
dose, only a small portion of total lead body
burden was removed because most lead bur-
den is in bone for both children and adults. A
longer treatment length (more than three
rounds) may reduce blood lead concentration
for a longer time (> 10 months), but such
treatments tend to be less feasible. The houses
of TLC trial children were cleaned up by vac-
uuming, mopping, minor repairing, and paint
stabilization to minimize continuous lead
exposure (Rogan et al. 2001). Study in adults
indicated that long-term lead accumulation
might increase blood pressure and risk of
hypertension (Cheng et al. 2001). We found
succimer increased systolic blood pressure
from 1 year to 5 years after treatment, but the
difference was very small and might have been
caused by something besides lead, such as cal-
cium excretion from the treatment (Graziano
et al. 1988). Calcium intake has been reported
to be inversely associated with blood pressure
in children (Gillman et al. 1992, 1995). It
may also be that despite adjustment for co-
variates, residual confounding (e.g., genetics,
dietary intake) still exists and contributes to
the small difference in systolic blood pressure
(Sinaiko 1996). Given these uncertainties, a
logical step to study the association between
lead exposure and blood pressure in children is
to seek direct evidence of such an association,
preferably by meta-analysis or pooled analysis.
Despite the limitations, this study had
larger sample size and repeated measurements
and thus more power and precision than previ-
ous studies in children. Common confounders
such as age, height, and BMI were adjusted for
in the analysis. The proportion of children
retained in the TLC study is high, and those
who remained in the follow-up did not differ in
treatment group, race, sex, and socioeconomic
status from those lost to follow-up.
The TLC trial children had much higher
blood lead levels than the mean of 2 µg/dL in
general U.S. children (Pirkle et al. 1998). It is
unlikely that background exposure will have
effects if the blood lead concentrations in the
TLC trial did not. Although there is no clear
evidence that the moderate lead exposure expe-
rienced by these children affected their blood
pressure, the associations between lead exposure
and decreased IQ in children and increased
blood pressure in adults render it an important
contributor to the global burden of disease
(Fewtrell et al. 2004), hardly diminished by
these relatively minor negative ﬁndings.
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